Telomerase activity levels in the surgical margin and tumour distant tissue of the squamous cell carcinoma of the head-and-neck

Analytical Cellular Pathology

Volumn 24, Issue 1, 2002, Pages 25-39

  Fabricius, Eva Maria ^a   Gurr, Ulrike ^a   Wildner, Gustav Paul ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

ELISA; Head and neck cancer; Squamous cell carcinoma; Surgical tumour margin; Telomerase; TRAP assay

Indexed keywords

TELOMERASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

EID: 0036360735     PISSN: 09218912     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/452527     Document Type: Article

References (98)

1. Semi-quantitative analysis of telomerase activity of exfoliated cells in urine of patients with urothelial cancers: Causative factors affecting sensitivity and specificity
2. Multiple head and neck tumors: Evidence for a common clonal origin
3. Onkologie 2000 - Denkbare entwicklungen für kopf-halstumoren
4. Mechanism of telomerase induction during T cell activation
5. Second primary tumors and field cancerization in oral and oropharyngeal cancer: Molecular techniques provide new insight and definitions
6. Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction
7. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck
8. Molecular staging of head and neck squamous carcinoma
9. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients
10. Genetc progression model for head and neck cancer: Implications for field cancerisation
11. Careful histological confirmation and microdissection reveal telomerase activity in otherwise telomerase-negative breast cancers
12. Telomerase activity and in situ telomerase RNA expression in oral carcinogenesis
13. + cells: Comparison with tumor mast-cell lines
14. Multiple primary tumours in patients with oral squamous cell carcinoma
15. Mutagen sensitivity as a biomarker for second primary tumors after head and neck squamous cell carcinoma
16. Mutagen sensitivity: Enhanced risk assessment of squamous cell carcinoma
17. Inflammatory cells and cancer: Think different!
18. Telomerase activity in oral squamous cell carcinoma
19. Telomeres, telomerase and cancer: An up-date
20. Actions of heparin that may affect the malignant process
21. Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix
22. Field cancerization, clonality, and epithelial stem cells: The spread of mutated clones in epithelial sheets
23. Minimal residual disease in head and neck cancer
24. Immunocytologic detection of isolated tumor cells in bone marrow of patients with squamous cell carcinomas of the nead and neck region
25. Detetion of circulating carcinoma cells by telomerase activity
26. Evidence for a causal association between human papillomavirus and a subset of head neck cancer
27. Detection of telomerase activity in human carcinomas using a trap-ELISA method: Correlation with hTR and hTERT expression
28. Cancer Statistics, 2001
29. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck
30. Telomerase, cell immortality, and cancer
31. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells
32. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues
33. Molecular targeting of cancer: Telomeres as targets
34. Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor
35. Telomerase activity in premalignant and malignant lesions of human oral mucosa
36. Specific association of human telomerase activity with immortal cells and cancer
37. Telomerase activation by the E6 gene product of human papillomavirus type 16
38. p53 gene mutations as marker of tumor spread in synchronous oral cancers
39. Telomerase, immortality and cancer
40. Telomerase activity as a potential marker in preneoplastic bladder lesions
41. Diagnostic and prognostic relevance of expression of human telomerase subunits in oral cancer
42. Localization of telomerase hTERT protein and survivin in placenta: Relation to placental development and hydatidiform mole
43. Telomerase activity in oral and maxillofacial tumors
44. Molecular markers of the risk of oral cancer
45. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes
46. Protein measurement with the folin phenol reagent
47. Molecular support for field cancerization in the head and neck
48. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues
49. Clinical implications of telomerase detection
50. Human papillomavirus (HPV) DNA in tonsillar cancer: Clinical correlates, risk of relapse, and survival
51. Role of telomerase in normal and cancer cells
52. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck
53. Telomerase activity and human papillomavirus in malignant, premalignant and benign cervical lesions
54. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma
55. Analysis of surgical margins with the molecular marker eIF4E: A prognostic factor in patients with head and neck cancer
56. Detection of the proto-oncogen eIF4E in surgical margins may predict recurrence in head and neck cancer
57. Regulation of mast cell growth and proliferation
58. Heparin, derived from the mast cells of human lungs is responsible for the generation of kinins in allergic reactions due to the activation of tha contact system
59. Staging of head and neck cancer
60. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow
61. Low-dose isotretinoin versus β-carotene to prevent oral carcinogenesis: Long-term follow-up
62. Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis
63. Global cancer statistics
64. Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment
65. Evaluation of telomerase activation in head and neck cancer
66. Correlation of telomerase activity, clinical prognosis and therapy in oral carcinogenesis
67. Mutagen sensitivity and environmental exposures as contributing causes of chromosome 3p losses in head and neck cancers
68. Mutagen sensitivity in patients with head and neck cancers: A biologic marker for risk of multiple primary malignancies
69. Synchronous oral carcinomas: Independent or common clonal origin?
70. A survey of telomerase activity in human cancer
71. The reactivation of telomerase activity in cancer progression
72. Telomerase and cancer
73. Molecular screening: Prospects for a new approach
74. "Field cancerization" in oral stratified squamous epithelium
75. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients
76. Comparison of histological grading and large-scale genomic status (DNA ploidy) as prognostic tools in oral dysplasia
77. DNA content as a prognostic marker in patients with oral leukoplakia
78. Telomerase and oral cancer
79. Telomerase components as a diagnostic tool in human oral lesions
80. Persistence of genetically altered fields in head and neck cancer patients: Biological and clinical implications
81. Non-radioactive semiquantitative testing for expression levels of telomerase activity in head and neck squamous cell carcinomas may be indicate for biological tumour behaviour
82. Effect of insulin-like growth factor 1 on PHA-stimulated cord blood mononuclear cell telomerase activity
83. Mapping of resection margins of oral cancer for p53 overexpression and chromocome instability to detect residual (pre)malignant cells
84. Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer
85. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: Methods, reliability, pitfalls, and solutions
86. Oral field cancerization: Carcinogen-induced independent events or micrometastatic deposits?
87. Telomerase activity in human solid tumors. Diagnostic utility and clinical applications
88. Head and neck cancer
89. Immunohistochemical localization of telomerase hTERT protein and analysis of clonality in multifocal vulvar intraepithelial neoplasia
90. Histological grading of oral epithelial dysplasia: Revisited
91. Minimal residual disease in thyroid carcinoma
92. Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays
93. Up-regulation of telomerase activity in human lymphocytes
94. Monoclonal antibodies against human telomerase reverse transcriptase (htert): Preparation, characterization, and application